严重血栓或易栓症患者的华法林剂量需求
结果显示临床实际维持剂量(平均6.9 mg/日)高于两种算法估算值(5.4 mg/日和5.2 mg/日),多易栓因素患者剂量最高,提示遗传算法可能低估剂量需求。
要点
- 严重血栓和/或易栓症患者华法林实际维持剂量高于遗传算法估算值
- 多易栓因素患者所需华法林剂量最高
- 遗传剂量算法可能低估此类患者的剂量需求
核心结论
- 在严重血栓和/或易栓症患者中,凝血酶生成和药效学变异影响华法林反应,遗传剂量算法似乎低估剂量需求。
研究设计与样本
- 华法林维持剂量(94%患者目标INR 2.0-3.0,6%目标INR 2.5-3.5)通过Gage和IWPC算法估算。
- 个体华法林维持剂量通过综合临床评估和INR数据进行调整。
主要发现
- 患者平均年龄47岁(范围20-76),BMI 27(SD 6),68%为女性。
- 40%携带CYP2C9*2或*3等位基因,54%携带VKORC1-1639A等位基因。
- Gage算法估算的每日平均维持剂量为5.4 mg(95%CI 4.9-5.9 mg),IWPC算法为5.2 mg(95%CI 4.7-5.7 mg)。
- 临床随访后的每日华法林维持剂量高于估算值,平均6.9 mg(95%CI 5.6-8.2 mg,P < 0.006),多易栓因素患者剂量最高(P < 0.03)。
临床怎么用
- 对于严重血栓和/或易栓症患者,遗传剂量算法估算的华法林剂量可能偏低,临床应结合综合评估和INR数据调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Warfarin dose requirement varies significantly. We compared the clinically established doses based on international normalized ratio (INR) among patients with severe thrombosis and/or thrombophilia with estimates from genetic dosing algorithms. METHODS: Fifty patients with severe thrombosis and/or thrombophilia requiring permanent anticoagulation, referred to the Helsinki University Hospital Coagulation Center, were screened for thrombophilias and genotyped for CYP2C9*2 (c.430C>T, rs1799853), CYP2C9*3 (c.1075A>C, rs1057910) and VKORC1 c.-1639G>A (rs9923231) variants. The warfarin maintenance doses (target INR 2.0-3.0 in 94%, 2.5-3.5 in 6%) were estimated by the Gage and the International Warfarin Pharmacogenetics Consortium (IWPC) algorithms. The individual warfarin maintenance dose was tailored, supplementing estimates with comprehensive clinical evaluation and INR data. RESULTS: Mean patient age was 47 years (range 20-76), and BMI 27 (SD 6), 68% being women. Forty-six (92%) had previous venous or arterial thrombosis, and 26 (52%) had a thrombophilia, with 22% having concurrent aspirin. A total of 40% carried the CYP2C9*2 or *3 allele and 54% carried the VKORC1-1639A allele. The daily mean maintenance dose of warfarin estimated by the Gage algorithm was 5.4 mg (95% CI 4.9-5.9 mg), and by the IWPC algorithm was 5.2 mg (95% CI 4.7-5.7 mg). The daily warfarin maintenance dose after clinical visits and follow-up was higher than the estimates, mean 6.9 mg (95% CI 5.6-8.2 mg, P < 0.006), with highest dose in patients having multiple thrombophilic factors (P < 0.03). CONCLUSIONS: In severe thrombosis and/or thrombophilia, variation in thrombin generation and pharmacodynamics influences warfarin response. Pharmacogenetic dosing algorithms seem to underestimate dose requirement.
引用
- Helin TA, Joutsi-Korhonen L, Asmundela H, et al. Warfarin dose requirement in patients having severe thrombosis or thrombophilia. Br J Clin Pharmacol. 2019. PMID: 30933373. doi:10.1111/bcp.13948
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。